Qiagen (NYSE:QGEN) Stock Holdings Increased by Janus Henderson Group PLC

Janus Henderson Group PLC increased its holdings in shares of Qiagen (NYSE:QGEN - Free Report) by 114.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 270,171 shares of the company's stock after purchasing an additional 144,112 shares during the period. Janus Henderson Group PLC owned 0.12% of Qiagen worth $11,999,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Brown Brothers Harriman & Co. acquired a new stake in Qiagen in the fourth quarter valued at $37,000. Geneos Wealth Management Inc. lifted its stake in shares of Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock valued at $38,000 after purchasing an additional 251 shares during the period. EverSource Wealth Advisors LLC grew its position in Qiagen by 152.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after buying an additional 526 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Qiagen by 148.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after acquiring an additional 835 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Qiagen by 83.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,565 shares of the company's stock worth $70,000 after acquiring an additional 712 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Trading Down 0.2%

Qiagen stock traded down $0.08 during midday trading on Tuesday, reaching $42.72. The stock had a trading volume of 911,934 shares, compared to its average volume of 1,145,919. The stock has a market capitalization of $9.50 billion, a PE ratio of 118.95, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. The stock's 50-day simple moving average is $41.03 and its 200 day simple moving average is $41.82. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.05. The company had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. Qiagen's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.44 earnings per share. Analysts expect that Qiagen will post 2.26 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on QGEN shares. UBS Group lowered their target price on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. StockNews.com raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Baird R W cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Finally, Robert W. Baird lifted their price objective on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Qiagen presently has a consensus rating of "Hold" and an average price target of $48.42.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.